Wednesday, June 10, 2026

pharma Β· Myotonic Dystrophy Type 1 Β· Myotonic Dystrophy Type 1 (DM1) Β· DYN

Dyne Therapeutics

Dyne Therapeutics clinical programs β€” 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Waltham, USA HQ
2018 Founded
276 Employees
Public company Type
DYN Β· NYSE Ticker
Company details
Status
Public
HQ
Waltham, USA
Founded
2018
Employees
276
Programs
6
Drugs
11
Patents
82
Intelligence Β· Clinical Programs

Dyne Therapeutics projects

4 ClinicalTrials.gov programs sponsored by Dyne Therapeutics.

Dyne Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. DYNE-101

    Dyne Therapeutics

    Myotonic Dystrophy Type 1 (DM1)

    phase 2 small molecule active

    1 trial
  2. DYNE-101 for Myotonic Dystrophy Type 1

    Dyne Therapeutics

    Myotonic Dystrophy Type 1

    phase 2 small molecule active

    1 trial
  3. DYNE-251

    Dyne Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial
  4. DYNE251-DMD-201

    Dyne Therapeutics

    Duchenne muscular dystrophy

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Dyne Therapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.